A61P 27 - Drugs for disorders of the senses

Patents for A61P 27 - Drugs for disorders of the senses (53,017)
11/2001
11/15/2001	WO2001085194A1 Method and composition for the treatment of angiogenesis
11/15/2001	WO2001085183A2 Preparation for the prevention and treatment of ocular disorders
11/15/2001	WO2001085169A2 R-eliprodil for treating glaucoma
11/15/2001	WO2001085152A2 R-eliprodil for treating glaucoma
11/15/2001	WO2001085149A2 Felbamate derived compounds
11/15/2001	WO2001084929A1 Antitubulin assembly and cell growth inhibitor denominated 'dioxostatin'
11/15/2001	WO2001055172A3 ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFRα PROTEIN
11/15/2001	WO2001040185B1 Compounds, compositions, and methods for stimulating neuronal growth and elongation
11/15/2001	WO2000047729A9 Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
11/15/2001	WO2000026370A9 Adenine nucleotide translocator (ant) fusion proteins and uses thereof
11/15/2001	US20010041726 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/15/2001	US20010041718 Cis-6-(4-fluoro-phenyl)-5-(4-(2-piperidin-1-yl-ethoxy)-phenyl) -5,6,7,8-tetrahydronaphthalene-2-ol, for example, and other estrogen agonists/antagonists to treat rheumatoid arthritis, colon cancer, wounds, cataracts and skin wrinkles
11/15/2001	US20010041710 (4R)-1-(4-(4-Fluorophenoxy)benzyl)-2-oxo-imidazolidine-4 -carboxylic acid hydroxyamide, for example; treating various diseases including osteoarthritis, rheumatoid arthritis, cancer, osteoporosis, strokes
11/15/2001	US20010041695 Orally administering to a post-menopausal woman a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine or salts
11/15/2001	US20010041671 Ophthalmic formulations
11/15/2001	CA2409759A1 Method and composition for the treatment of angiogenesis
11/15/2001	CA2409758A1 Novel multicyclic compounds and the use thereof
11/15/2001	CA2409729A1 5-ht7 receptor antagonists
11/15/2001	CA2408349A1 Method of regulating angiogenesis unsing ryk protein
11/15/2001	CA2408293A1 Novel vitronectin receptor antagonists
11/15/2001	CA2408220A1 Antitubulin assembly and cell growth inhibitor denominated "dioxostatin"
11/15/2001	CA2407852A1 Ortho-substituted anthranilic acid amides and their use as medicaments
11/15/2001	CA2407830A1 Amino acid derivatives and their use as medicines
11/15/2001	CA2407817A1 Anthranilamides and their use as pharmaceutical agents
11/15/2001	CA2407697A1 Felbamate derived compounds
11/15/2001	CA2406549A1 R-eliprodil for treating glaucoma
11/14/2001	EP1153302A1 Diagnostics and therapeutics for macular degeneration
11/14/2001	EP1153301A1 Diagnostics and therapeutics for arterial wall disruptive disorders
11/14/2001	EP1153125A1 Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
11/14/2001	EP1153121A2 Secreted proteins and polynucleotides encoding them
11/14/2001	EP1153038A1 Therapeutics and diagnostics based on a il-1b mutation
11/14/2001	EP1153015A1 Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases
11/14/2001	EP1152770A1 Small peptides and methods for treatment of asthma and inflammation
11/14/2001	EP1125575A9 Perfusate preparation for ophthalmic operation
11/14/2001	EP0862431B1 Use of a paediatric pharmaceutical formulation comprising amoxycillin and clavulanate
11/14/2001	EP0812198B1 Stabilization of prostaglandin compositions
11/14/2001	EP0777482B1 Combined preparation for the therapy of immune diseases
11/14/2001	CN1322246A Restin and methods of use thereof
11/14/2001	CN1322212A Neuropeptide Y agaonists
11/14/2001	CN1322202A Quinazoline derivatives
11/14/2001	CN1322194A Substituted phenyl derivatives, their preparation and use
11/14/2001	CN1321639A Substd. heterocyclic compounds, preparing process thereof and pharmaceutical composition contg them
11/14/2001	CN1321634A Substd heterocyclic compounds preparing method thereof and pharmaceutical composition contg. them
11/14/2001	CN1321500A Method for preventing and curing diseases by using kakonein preparation
11/14/2001	CN1321499A Chinese patent medicine for curing deafness
11/13/2001	US6316472 Heterosubstituted pyridine derivatives as PDE 4 inhibitors
11/13/2001	US6316457 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
11/13/2001	US6316009 Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharamaceutical and cosmetic compositions containing same
11/08/2001	WO2001084149A2 Diagnostics and therapeutics for macular degeneration-related disorders
11/08/2001	WO2001083729A2 Vectors for ocular transduction and use thereof for genetic therapy
11/08/2001	WO2001083554A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083547A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083516A1 Laminin 15 and uses thereof
11/08/2001	WO2001083510A1 29 human secreted proteins
11/08/2001	WO2001083472A1 Muscarinic agonists
11/08/2001	WO2001083440A2 Synthesis and use of thienotriazolodiazepines
11/08/2001	WO2001082984A2 Low ionic strength ophthalmic compositions
11/08/2001	WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001	WO2001082933A2 Compositions and methods for stabilizing modified tissue
11/08/2001	WO2001082913A2 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
11/08/2001	WO2001068070A8 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001	WO2001034183A3 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
11/08/2001	WO2001030383A3 Medicament in order to induce tolerance
11/08/2001	WO2001029012A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	WO2001029011A3 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
11/08/2001	WO2001008707A3 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/08/2001	WO2000074666A3 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
11/08/2001	US20010039438 Method for treating neovascularization
11/08/2001	US20010039289 Antagonists; especially sodium salts
11/08/2001	US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001	US20010039271 For treatment of male erectile dysfunction, female sexual dysfunction
11/08/2001	US20010039038 Novel glucosaminidase
11/08/2001	US20010038860 As active ingredient a hydrophilic polymer mainly composed of monomeric units of alkylene glycols and/or vinyl monomeric units having a nondissociating hydrophilic group
11/08/2001	US20010038847 Subjecting animal pericardium to multiple steps of freezing and thawing in a salt solution, and incubating in a solution of ammonia and ethyl alcohol to produce a biological material for use in ophthalmology such as antiglaucoma drainage tube
11/08/2001	US20010038838 Empiric treatment of infections potentially caused by drug resistance streptococcus pneumoniae in a human patient comprising the oral administration of a formulation comprising amoxycillin and potassium clavulanate
11/08/2001	CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2407914A1 Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
11/08/2001	CA2407881A1 Vectors for ocular transduction and use thereof for genetic therapy
11/08/2001	CA2407797A1 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	CA2407785A1 Use of .alpha.-msh and epo for preventing or treating ischemic conditions
11/08/2001	CA2407594A1 Muscarinic agonists
11/08/2001	CA2403901A1 29 human secreted proteins
11/07/2001	EP1152055A1 ADAMTS polypeptides, nucleic acids encoding them, and uses therof
11/07/2001	EP1151101A1 Prostacyclin-stimulating factor-2
11/07/2001	EP1151012A1 Rhamm antagonist antibodies
11/07/2001	EP1151008A1 Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
11/07/2001	EP1150997A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
11/07/2001	EP1150976A1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase
11/07/2001	EP1150965A1 Benzazepine derivatives as alpha-v integrin receptor antagonists
11/07/2001	EP1150960A1 Polymorphic crystalline forms of celecoxib
11/07/2001	EP1150959A1 Solid-state form of celecoxib having enhanced bioavailability
11/07/2001	EP1150678A1 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
11/07/2001	EP1150676A1 Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
11/07/2001	EP1150666A1 Stimulating neutrophil function to treat inflammatory bowel disease
11/07/2001	EP0758452B1 Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
11/07/2001	CN1321158A Tricyclic delta 3-piperidines as pharmaceuticals

1 ... 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 ... 531